Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionM&t Bank Corp
Latest Disclosed Ownership7,865 shares
Latest Disclosed Value $ 2,602,293
M&t Bank Corp reports 1.27% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - M&t Bank Corp filed a 13F-HR form disclosing ownership of 7,865 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $2,247,030 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on January 30, 2026 disclosing 7,966 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -1.27% during the quarter. The current value of the position is $2,048,832 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,865 -101 -1.27 2,602 -17.84 0.0021
2026-01-30 2025-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 7,966 1,164 17.11 3,167 2.13 0.0102
2026-01-28 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,781 -21 366 0.0002
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,802 -1,401 -17.08 3,102 15.97 0.0104
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,203 335 4.26 2,674 25.89 0.0092
2025-04-30 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,868 -740 -8.60 2,125 4.89 0.0077
2025-02-06 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,608 -37 -0.43 2,025 -14.81 0.0068
2024-11-19 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,645 206 2.44 2,377 15.89 0.0078
2024-07-31 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,439 2,013 31.33 2,051 113.65 0.0070
2024-05-07 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,426 -369 -5.43 960 -26.15 0.0033
2024-02-06 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,795 -179 -2.57 1,301 5.26 0.0048
2023-11-02 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,974 124 1.81 1,236 -5.00 0.0049
2023-08-09 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,850 -20 -0.29 1,301 -5.45 0.0049
2023-05-11 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,870 661 10.65 1,376 -6.78 0.0053
2023-02-13 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 6,209 -423 -6.38 1,476 11.15 0.0059
2023-02-13 2022-12-31 13F ALLY FINL COM 02043Q107 6,590 -42 1,474 0.0059
2022-11-17 2022-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 6,632 2,089 45.98 1,327 100.45 0.0059
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,632 2,089 1,322 0.0011
2022-08-05 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,543 -119 -2.55 662 -13.24 0.0031
2022-05-09 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,662 1,075 29.97 763 25.49 0.0034
2022-02-07 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,587 15 0.42 608 -9.79 0.0026
2021-10-28 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,572 15 0.42 674 11.59 0.0030
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,557 -120 -3.26 604 16.38 0.0027
2021-05-06 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,677 -130 -3.41 519 4.85 0.0022
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,807 -99 -2.53 495 -13.01 0.0022
2020-11-06 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,906 -313 -7.42 569 -9.11 0.0028
2020-07-29 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,219 536 14.55 626 55.72 0.0034
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,683 -438 -10.63 402 -15.37 0.0024
2020-02-07 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,121 -712 -14.73 475 22.42 0.0022
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,833 157 3.36 388 14.45 0.0019
2019-08-12 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,676 -625 -11.79 339 -31.52 0.0018
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,301 -4 -0.08 495 27.91 0.0026
2019-02-01 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,305 188 3.67 387 -13.62 0.0022
2018-11-09 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,117 381 8.04 448 -3.86 0.0022
2018-08-10 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,736 523 12.41 466 -7.17 0.0025
2018-05-04 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,213 103 2.51 502 -3.83 0.0027
2018-02-06 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,110 50 1.23 522 9.43 0.0027
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,060 -70 -1.69 477 44.11 0.0026
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,130 4,130 331 0.0020
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,818 -100.00 0 -100.00
2016-11-04 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,818 4,818 0.00 326 0.0021
2016-08-04 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,896 -100.00 0 -100.00
2016-05-11 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,896 -3,187 -39.43 307 -59.66 0.0021
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,083 2,174 36.79 761 60.21 0.0051
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,909 -3,625 -38.02 475 -58.44 0.0032
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,534 -379 -3.82 1,143 10.43 0.0069
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,913 -13 -0.13 1,035 7.59 0.0065
2015-02-12 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,926 -2,169 -17.93 962 1.80 0.0060
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,095 12,095 945 0.0066
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.